Abcam, ab284411, Anti-PIRB antibody [EPR24885-18] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal LIRB3 antibody. Carrier free. Suitable for ICC/IF, IP, WB, IHC-P, IHC-Fr and reacts with Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24885-18,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse,
Applications:IHC-Fr, ICC/IF, IP, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Paired immunoglobulin-like receptor B commonly known as PIR-B is an inhibitory receptor expressed in various immune cells like macrophages dendritic cells and B cells. PIR-B often weighs around 129 kDa. It consists of extracellular immunoglobulin domains and intracellular immunoreceptor tyrosine-based inhibition motifs (ITIMs). This receptor is a part of the immune system machinery where it interacts with major histocompatibility complex (MHC) class I molecules which makes it a point of interest in understanding immune responses and signaling.
Biological function summary
PIR-B plays a role in immune regulation and tolerance. It is involved in inhibiting signaling pathways that activate immune cells. PIR-B forms a part of signal regulatory complex working alongside other receptors in the immune system to maintain a balanced immune response. By interacting with ITIMs PIR-B recruits phosphatases which de-phosphorylate signaling molecules leading to reduced cellular activation. This inhibitory mechanism ensures the prevention of excessive immune responses which can cause tissue damage.
Pathways
The immune regulation by PIR-B is important in innate and adaptive immunity. PIR-B integrates its function into pathways such as the negative regulation of immune effector processes and signal transduction. PIR-B has similarity with proteins like CD300 and ILT family involved in controlling immune response by hindering excessive cellular activation. Its action contributes significantly to homeostasis by regulating signal transduction processes during immune responses.
PIR-B has a relationship with autoimmune diseases and certain cancers. Its expression and inhibitory function relate to conditions like rheumatoid arthritis and lymphoma. In rheumatoid arthritis PIR-B's interaction with MHC class I molecules and phosphatases like SHP-1 and SHP-2 modulates the immune response and may contribute to disease pathogenesis. In some cancers the dampening of immune responses by PIR-B might facilitate tumor evasion from immune surveillance making it a potential target for therapeutic intervention.